# Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis

> **NCT04305327** · PHASE3 · TERMINATED · sponsor: **LEO Pharma** · enrollment: 12 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Brodalumab
- **DRUG:** Ustekinumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04305327
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-07
- **Primary completion:** 2023-05-05
- **Final completion:** 2023-05-05
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Early terminated due to difficulty recruiting participants
- **Last updated:** 2025-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04305327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04305327, "Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT04305327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*